Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study
September 06, 2022 08:00 ET
|
Noema Pharma
Study to validate the novel Patient-Reported Electronic Diary designed to more efficiently and accurately measure disease burden associated with trigeminal neuralgiaLIBRATN (NOE-101 Phase 2/3 study in...
Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder
August 04, 2022 08:00 ET
|
Noema Pharma
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line data expected in Q4 2023 BASEL, Switzerland and...
Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder
June 27, 2022 08:00 ET
|
Noema Pharma
Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line data expected in Q4 2023 BASEL, Switzerland and BOSTON,...
Noema Pharma to Attend and Present at BioEquity Europe and UBS Global Healthcare Conference in May 2022
May 06, 2022 08:00 ET
|
Noema Pharma
BASEL, Switzerland, May 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi...
Noema Pharma to Attend and Present at Stifel 2022 CNS Days
March 25, 2022 08:00 ET
|
Noema Pharma
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it...
Noema Pharma Appoints Michael Gutch as Chief Financial Officer
February 28, 2022 08:00 ET
|
Noema Pharma
BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of...
Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
February 22, 2022 08:00 ET
|
Noema Pharma
Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage...
Noema Pharma Announces FDA Investigational New Drug Authorization for Phase 2b LibraTN Study of mGluR5 Inhibitor NOE-101 in Trigeminal Neuralgia
February 14, 2022 08:00 ET
|
Noema Pharma
Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage...
Noema Pharma to Host Key Opinion Leader Webinar on Trigeminal Neuralgia “Trigeminal Neuralgia? You are not alone”
February 08, 2022 08:00 ET
|
Noema Pharma
Friday, February 11th 2012 - 12 pm EST / 6 pm CET Featuring Dr. Joanna Zakrzewska from University College London Hospital andTerence J. Coderre, Ph.D. from McGill University BASEL, Switzerland,...
Noema Pharma Hosting Key Opinion Leader Webinar on Stuttering
December 08, 2021 02:00 ET
|
Noema Pharma
BASEL, Switzerland, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will host a...